Abstract Number: PB2167
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » Cancer Associated Thrombosis
Background: Venous thromboembolism (VTE), including pulmonary embolism (PE), require new diagnostic strategies and therapeutic approaches. Upon activation, neutrophils release their content by degranulation or NETosis. NETs are highly prothrombotic networks made of DNA, myeloperoxidase (MPO), calprotectin and nucleosomes, among other neutrophil molecules. Furthermore, new biomarkers are needed to early identify cancer patients with high thrombotic risk.
Aims: To study the markers of neutrophil activation in PE and cancer-associated VTE patients.
Methods: 18 (8 PE patients and 10 cancer-associated VTE patients) and 12 healthy subjects were prospectively recruited. Plasma markers of neutrophil activation (cell-free DNA, MPO, calprotectin and nucleosomes) were measured in the totality of the samples. Statistical analysis of differentially expressed neutrophil activation markers among all groups was performed using GraphPad Prism (v8.0.1).
Results: We compared each plasma markers of neutrophil activation by an ANOVA analysis. Compared to controls, PE patients had higher concentration of plasma calprotectin (P=0.028), cfDNA (P=0.0067) and MPO (P=0.028). Similarly cancer-associated VTE patients had increased levels of plasma calprotectin (P< 0.0001) and DNA (P< 0.0001) than controls. A significant correlation was observed between calprotectin and cfDNA levels (Spearman r=0.812, P< 0.001), between calprotectin and nucleosomes levels (r=0.538, P=0.003), calprotectin and MPO levels (r=0.557, P< 0.002) and between MPO and cfDNA levels (r=0.508, P=0.005).This significant correlations indicate that they all had to some extent the same origin. As expected, no differences were observed between PE and cancer-associated VTE patients since both are highly prothrombotic states.
Conclusions: An increase in plasma markers of neutrophil activation may reflect a highly prothrombotic state and, when confirmed, may be valuable for the identification of high-risk patients including those with a neoplastic disease. Funding sources: Instituto de Salud Carlos III (PI15/01085, PI17/00495) and SETH.
To cite this abstract in AMA style:
Oto J, Sánchez-López V, Arellano E, Elias T, Jara L, Asensio MI, Otero R, Medina P. Differential Expression of Neutrophil Activation Markers in Venous Thromboembolism Patients with and without Association to Cancer [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/differential-expression-of-neutrophil-activation-markers-in-venous-thromboembolism-patients-with-and-without-association-to-cancer/. Accessed October 1, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/differential-expression-of-neutrophil-activation-markers-in-venous-thromboembolism-patients-with-and-without-association-to-cancer/